Comparison of inhaled albuterol powder and aerosol in asthma

Edwin Bronsky, Gerald A. Bucholtz, William W. Busse, Paul Chervinsky, John Condemi, Mohammed A. Ghafouri, Leonard Hudson, S. Lakshminarayan, Richard Lockey, Marshall E. Reese, Stephen I. Rennard, Allen Segal, Laurence Smolley, Sheldon Spector, John J. Stablein, Andre Van As, Archie Wilson

Research output: Contribution to journalArticlepeer-review

31 Scopus citations


In this multicenter, randomized, double-blind study comparing the efficacy and safety of aerosolized albuterol with the dry powder formulation, 231 patients with chronic reversible obstructive airway disease were randomly allocated to receive either placebo albuterol aerosol followed immediately by active albuterol powder (200 μg) or active albuterol aerosol (two puffs, 180 μg) followed immediately by placebo lactose powder four times a day for a period of 12 weeks. No statistically significant differences were found between the powder and aerosol formulations with respect to pulmonary function, length of time mean FEV1 remained ≥15% above baseline, physicians' assessments of patients' clinical response, or patients' subjective symptom scores. There were also no significant differences between treatment groups in cardiovascular effects, laboratory values, or adverse events. Among patients who expressed a preference for one of the delivery systems, half preferred using the powder. Results of this study demonstrate that 200 μg of albuterol powder is as safe and effective as 180 μg of albuterol aerosol.

Original languageEnglish (US)
Pages (from-to)741-747
Number of pages7
JournalThe Journal of Allergy and Clinical Immunology
Issue number5
StatePublished - May 1987
Externally publishedYes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Comparison of inhaled albuterol powder and aerosol in asthma'. Together they form a unique fingerprint.

Cite this